1 Gustave Roussy, DITEP, Gustave Roussy, Villejuif, France. yohann.loriot@gustaveroussy.fr.
2 INSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France. yohann.loriot@gustaveroussy.fr.
3 PRISM, Gustave Roussy, Villejuif, France. yohann.loriot@gustaveroussy.fr.
4 Department of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France. maud.kamal@gustaveroussy.fr.
5 Bioinformatics and Computational Systems Biology of Cancer, Institut Curie, PSL Research University, Mines Paris Tech, INSERM U900, 75005, Paris, France.
6 Université Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-, 75018, Paris, France.
7 Department of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France.
8 INSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
9 Gustave Roussy, DITEP, Gustave Roussy, Villejuif, France.
10 Biopath department, Gustave Roussy, Villejuif, France.
11 Department of interventional radiology, Gustave Roussy, Villejuif, France.
12 Department of Radiothérapie, Institut Curie, 75005 Paris & 92210 Saint-Cloud, Paris, France.
13 PRISM, Gustave Roussy, Villejuif, France.
14 Department of Urology, Foch Hospital, Suresnes, France.
15 Department of Genetics, Institut Curie, 75005, Paris, France.
16 UMR144, Institut Curie, 75005, Paris, France.
17 Biometry unit, direction of clinical research, Institut Curie, 75005, Paris, France.
18 Department of Pathology, Institut Curie, PSL Research University, 75005, Paris, France.
19 Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
20 INSERM U1016, Faculty of Pharmaceutical and Biological Sciences, Université Paris Cité, Paris, France.